Results 111 to 120 of about 145,684 (315)

Convergence of Epidemiology and Modifiable Causal Risk Factors in Inflammatory Bowel Disease and Alzheimer’s Disease

open access: yesBIO Integration
Background: Inflammatory bowel disease (IBD) and Alzheimer’s disease (AD) are major global health burdens that are rising in prevalence but are typically studied as distinct disorders.
Liuxi Chu   +15 more
doaj   +1 more source

Lymphocyte homing and its role in the pathogenesis of IBD

open access: yes, 2008
Inflammatory bowel disease (IBD) is an idiopathic disorder of chronic inflammation of the gastrointestinal tract. Experimental models of IBD and results from genornewide linkage Studies suggest that the primary defect that leads to IBD is an ...
Eksteen, Johannes   +2 more
core   +1 more source

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk   +5 more
wiley   +1 more source

Kajian Serologis Dan Molekuler Ayam Pedaging Yang Divaksinasi Menggunakan Vaksin Infectious Bursal Disease (IBD) Berbagai Tingkat Dosis

open access: yes, 2012
Disease of Infectious bursal disease (IBD) is a viral disease that causes economic losses to the poultry industry as it causes high mortality and immunosuppression. IBD disease prevention efforts carried out by means of vaccination and biosecurity.
Indriawati
core  

Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse   +3 more
wiley   +1 more source

What's the next best cytokine target in IBD?

open access: yes, 2012
In the gut of patients with inflammatory bowel disease (IBD), immune and nonimmune cells produce large amounts of cytokines that drive the inflammatory process leading to the tissue damage. Cytokine blockers, such as anti-tumor necrosis factor alpha (TNF-
MacDonald, Thomas T   +3 more
core   +1 more source

The decline of 6‐thioguanine nucleotides is not linked to impaired efficacy or safety of thiopurines in pregnant women with inflammatory bowel disease

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Background Thiopurines are used to maintain remission in inflammatory bowel disease (IBD). These drugs are metabolized into 6‐thioguanine nucleotides (6‐TGN), associated with efficacy, and 6‐methylmercaptopurine ribonucleotides (6‐MMPR), associated with adverse drug reactions. Pregnancy has been linked to a shift in thiopurine metabolism, characterized
Dianne G. Bouwknegt   +13 more
wiley   +1 more source

Seroepidemiology of Infectious Bursal Disease in Poultry Reared Under Backyard Production System in Wolaita Zone, Southern Ethiopia

open access: yesVeterinary Medicine: Research and Reports, 2022
Mihret Amajo,1 Asamnew Tesfaye,2 Teshale Sori,3 Haileleul Negussie3 1School of Veterinary Medicine, College of Agriculture, Wolaita Sodo University, Wolaita Sodo, Ethiopia; 2National Animal Health Diagnostic and Investigation Center, Sebeta, Ethiopia ...
Amajo M, Tesfaye A, Sori T, Negussie H
doaj  

Dysregulated Immunity to Clostridioides difficile in IBD Patients Without a History of Recognized Infection

open access: yes
BACKGROUND & AIMS: Clostridioides difficile is a toxin-secreting bacteria that is an urgent antimicrobial resistance threat, with approximately 25% of patients developing recurrent infections.
Wang, X   +13 more
core   +1 more source

Home - About - Disclaimer - Privacy